Stocks
Adaptive Biotechnologies Financial Statements (ADPT) |
||||||||||
| Adaptive Biotechnologiessmart-lab.ru | % | 2023Q2 | 2023Q3 | 2023Q4 | 2023Q4 | 2024Q1 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 02.08.2023 | 09.11.2023 | 31.12.2023 | 29.02.2024 | 07.05.2024 | 07.05.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 48.9 | 37.9 | 45.8 | 45.8 | 41.9 | 171.4 | |||
| Operating Income, bln rub | -47.8 | -51.0 | -45.6 | -45.6 | -48.8 | -191.0 | ||||
| EBITDA, bln rub | ? | -38.6 | -51.0 | -40.2 | -40.2 | -39.3 | -170.8 | |||
| Net profit, bln rub | ? | -47.8 | -50.3 | -69.4 | -69.4 | -47.5 | -236.7 | |||
| OCF, bln rub | ? | -23.6 | -46.7 | 10.8 | -26.9 | -38.4 | -101.2 | |||
| CAPEX, bln rub | ? | 3.70 | 2.78 | 0.000 | 1.30 | 1.51 | 5.59 | |||
| FCF, bln rub | ? | -27.3 | -49.5 | 10.8 | -28.2 | -39.9 | -106.8 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 78.8 | 69.5 | 71.4 | 66.4 | 72.6 | 279.9 | ||||
| Cost of production, bln rub | 17.9 | 19.3 | 20.0 | 25.0 | 18.1 | 82.5 | ||||
| R&D, bln rub | 32.2 | 28.5 | 28.7 | 23.8 | 30.2 | 111.3 | ||||
| Interest expenses, bln rub | 3.61 | 3.65 | 3.01 | 3.01 | 2.99 | 12.7 | ||||
| Assets, bln rub | 764.5 | 717.7 | 661.1 | 661.1 | 620.3 | 620.3 | ||||
| Net Assets, bln rub | ? | 396.0 | 361.7 | 308.3 | 308.4 | 274.9 | 274.9 | |||
| Debt, bln rub | 103.5 | 101.3 | 98.8 | 229.4 | 96.5 | 96.5 | ||||
| Cash, bln rub | 417.2 | 371.1 | 346.4 | 346.4 | 308.9 | 308.9 | ||||
| Net debt, bln rub | -313.7 | -269.8 | -247.6 | -117.0 | -212.4 | -212.4 | ||||
| Ordinary share price, rub | 6.71 | 5.45 | 4.90 | 4.90 | 3.21 | 4.87 | ||||
| Number of ordinary shares, mln | 144.4 | 144.7 | 144.9 | 144.9 | 145.8 | 145.8 | ||||
| Market cap, bln rub | 969 | 789 | 710 | 710 | 468 | 710 | ||||
| EV, bln rub | ? | 655 | 519 | 462 | 593 | 256 | 498 | |||
| Book value, bln rub | 271 | 237 | 189 | 184 | 151 | 151 | ||||
| EPS, rub | ? | -0.33 | -0.35 | -0.48 | -0.48 | -0.33 | -1.62 | |||
| FCF/share, rub | -0.19 | -0.34 | 0.07 | -0.19 | -0.27 | -0.73 | ||||
| BV/share, rub | 1.88 | 1.64 | 1.31 | 1.27 | 1.04 | 1.04 | ||||
| EBITDA margin, % | ? | -78.8% | -134.4% | -87.9% | -87.9% | -93.9% | -99.7% | |||
| Net margin, % | ? | -97.7% | -132.7% | -151.7% | -151.7% | -113.5% | -138.1% | |||
| FCF yield, % | ? | -17.5% | -21.7% | -18.0% | -23.5% | -30.9% | -15.0% | |||
| ROE, % | ? | -45.3% | -51.0% | -74.4% | -74.3% | -78.2% | -86.1% | |||
| ROA, % | ? | -23.4% | -25.7% | -34.7% | -34.7% | -34.7% | -38.2% | |||
| P/E | ? | -5.41 | -4.28 | -3.10 | -3.10 | -2.18 | -3.00 | |||
| P/FCF | -5.71 | -4.60 | -5.55 | -4.25 | -3.23 | -6.65 | ||||
| P/S | ? | 5.11 | 4.39 | 4.17 | 4.17 | 2.68 | 4.14 | |||
| P/BV | ? | 3.57 | 3.32 | 3.75 | 3.85 | 3.09 | 4.69 | |||
| EV/EBITDA | ? | -4.03 | -2.97 | -2.59 | -3.32 | -1.51 | -2.91 | |||
| Debt/EBITDA | 1.93 | 1.55 | 1.39 | 0.66 | 1.26 | 1.24 | ||||
| R&D/CAPEX, % | 872.0% | 1 027% | 1 832% | 2 002% | 1 992% | |||||
| CAPEX/Revenue, % | 7.56% | 7.33% | 0.00% | 2.84% | 3.61% | 3.26% | ||||
| Adaptive Biotechnologies shareholders | ||||||||||
